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Abstract 
Purpose: The purpose of this project was to implement a change in workflow to increase 
colorectal cancer (CRC) screening rates and improve Meaningful Use scores in a primary care 
setting.  
Background and Significance: CRC is the second leading cause of cancer-related deaths in the 
United States among men and women. Current CRC screening rates remain low, even with 
advanced screening options available. Meaningful Use sets specific objectives for health care 
providers to achieve. Documenting CRC screening status and recommending CRC screenings to 
patients is one of the objectives of Meaningful Use and is considered a Clinical Quality Measure 
(HealthIT.gov). Factors that lead to CRC screening include primary care providers (PCPs) 
raising the topic, involving support staff, involving patients in the decision-making process, and 
setting alerts in electronic health records (EHRs).  
Methods: The Health Belief Model and Ottawa Model of Research Use helped guide this 
project. The project took place at a private primary care practice. The focus was on patients 
between the ages of 50 and 75 years old meeting criteria for CRC. Five PCPs and five medical 
assistants (MAs) chose to participate in the study. Participants were given pre and post Practice 
Culture Assessment (PCA) surveys to measure perceptions of the practice culture. The project 
included a three-part practice change: PCP and MA education about CRC screening guidelines, 
EHR documentation and reminders, and a change of patient visit workflow which included 
having MAs review patient's CRC screening status before they were seen by the PCP, and 
handing out CRC screening brochures when appropriate. PCPs then ordered the appropriate CRC 
screening, and the MA documented the screening in the EHR under a designated location. CRC 
Screening Project Evaluation Forms were completed by MAs after each patient visit.  
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Outcomes: No significant difference from pre to post survey satisfaction scores were found (t 
(8) = -1.542, p = .162). Means of quantitative data were reported from the CRC screening 
evaluation forms; N=91. The most common method of screening chosen was colonoscopy, 87%. 
A strong correlation was found (r (-.293) = .01, p <.05) between receiving a CRC brochure and 
choosing a form of screening. Meaningful Use scores post intervention were inconclusive as data 
was not made available by the site. 
Conclusions: Patients are more likely to choose a screening method when the topic is raised in a 
primary care setting. Continued staff education on workflow is important to sustain this change. 
Further research is needed to evaluate cost effectiveness and sustainability of this practice 
change. 
 Keywords: colorectal cancer, primary care, screening, Meaningful Use 
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Increasing Colorectal Cancer Screening in the Primary Care Setting 
 This paper introduces the topic of colorectal cancer, its prevalence in the Unites States, 
the importance of cancer screenings, and the ways in which advanced practice nurses can have 
an impact on its outcomes. 
 Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the 
United States among men and women, even with the current screening options available. 
Worldwide, CRC is the third most common cancer, affecting approximately 1.4 million people in 
2012 (World Cancer Research Fund International, 2017). In 2016, approximately 134,000 people 
were diagnosed with CRC, accounting for approximately 49,000 deaths (US Preventive Services 
Task Force [USPSTF], 2016). The USPSTF finds that "screening for colorectal cancer is a 
substantially underused preventive health strategy in the United States" (US Preventive Services 
Task Force, 2016). In addition, one of the goals of Healthy People 2020 is to reduce the number 
of cancer-related deaths through early detection and treatment (Healthypeople.gov, 2017). The 
USPSTF currently recommends screening for colorectal cancer for both men and women 
between the ages of 50 to 75 years. Screenings are recommended for patients that are at average 
risk and who are asymptomatic, meaning no family or personal history of CRC, blood in their 
stool, iron deficiency anemia, or personal history of irritable bowel disease (IBD) or Crohn's 
disease (US Preventive Services Task Force, 2016). According to the Colon Cancer Alliance 
(2017), 50% of new CRC cases occur in people age 50 and older. People with first degree 
relatives who have had CRC have increased risk, and should be screened earlier. It is 
recommended that African Americans have their first screening at the age of 45 years.  
 Current CRC screening rates remain low, even with advanced screening options 
available. It is estimated that only one in three adults receive some form of CRC screening 
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between the ages of 50 to 75 years (American Gastroenterological Association, 2017). Colorectal 
cancer can be caught early with regular screenings. Early detection and treatment leads to better 
patient outcomes and improved mortality. The USPSTF recently changed its statement on the 
best way to screen for CRC, stating that any form of screening is better than no screening at all. 
They do not list screening tests in any order preference, though colonoscopy remains the gold 
standard (Hite and Margolin, 2016). Available screenings methods include colonoscopy, flexible 
sigmoidoscopy, computed tomography colonoscopy, the guaiac fecal occult blood test (FOBT), 
the fecal immunochemical test (FIT), stool DNA test, and the SEPT9 DNA test (US Preventive 
Services Task Force, 2016).  These screening options all have their own unique risks and 
benefits to their testing. Some can be completed by the patients themselves in the privacy of their 
home, while endoscopies must be completed in a surgical setting, often with sedation. Overall, 
CRC is a common cancer affecting millions of people in the United States each year. Multiple 
guidelines recommend screening for CRC between the ages of 50 to 75 years, and yet screening 
rates remain low, leading to increased mortality.  
Background and Significance  
There are multiple guidelines recommending the routine screening for colorectal cancer (CRC) 
in people between the ages of 50 to 75 years old. The conventional screening methods include 
invasive tests, such as endoscopy/colonoscopy, as well as stool tests that are noninvasive. 
However, there are newer screening options available that have the potential to improve CRC 
screening rates by offering noninvasive testing in the home setting (Imperiale et al., 2014; Hite & 
Margolin, 2016; Patel & Kilgore,2015). The U.S. Preventative Services Task Force (USPSTF) 
(2016) has updated its position statement on routine CRC screenings, stating that any form of 
CRC is acceptable and better than no CRC screening being done at all. This gives more options 
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to providers and allows the opportunity to offer noninvasive screening tests in addition to the 
standard invasive colonoscopy procedure.  
 Hagoel, Neter, Stein, and Rennert (2016) found that in order to increase CRC screenings, 
the topic of CRC must be posed by the provider. This sounds simple and even obvious, but it is 
not always being carried out in practice. If screening options and prompts are not provided by 
primary care providers routine CRC screening rates will not improve. Primary care providers 
face many barriers to recommending CRC screenings, including lack of time, logistics, 
inconvenience, and provider forgetfulness (Spruce and Sanford, 2012). System barriers include 
lack of health insurance, no reminder systems, lack of time, and no access to colonoscopy 
(Spruce & Sanford, 2012). Dolan, Boohaker, Allison, and Imperiale (2013) found that patient 
preference of screening tests is an important factor in deciding which screening test, if any, to 
complete.  Each testing option comes with limitations, risks, and benefits. With colonoscopy, 
there is risk of post procedure bleeding, rupture, and infection. Colonoscopy also requires a 
bowel preparation, transportation to and from the testing facility, time away from work, and 
frequently sedation. These risks should be considered and discussed with patients thoroughly 
when recommending them for screening (Bibbins-Domingo et al., 2016). Stool based testing, 
pose less risks, but a risk includes false positive results that can lead to unnecessary follow-up 
testing (US Preventive Services Task Force, 2016).  This method also requires patients to handle 
their own stool, which could be a deterrent for some. In addition, there is the opportunity for 
patients to turn in samples from other family members, while claiming it as their own to avoid 
further testing. 
 There are multiple studies showing multitarget stool DNA (mt-sDNA) tests having 
increased sensitivity in detecting CRC compared to fecal immunochemical test (FIT) testing 
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(Fitzpatrick-Lewis et al., 2016; Imperiale et al., 2014; Malik, 2016). In 2014 the US Food and 
Drug Administration approved the first mt-sDNA test under the brand name Cologuard. Its use is 
gaining wide popularity among primary care physicians and is now covered through Medicare. 
With Medicare offering coverage for this test, it is believed that private insurance companies will 
soon be covering it as well. Patel & Kilgore (2015) found any form of CRC screening to be more 
cost effective than having no screening at all, by using incremental cost-effectiveness ratios 
(ICERs). The highest ICER was for stool DNA testing every 5 years. However, it is still unclear 
as to which screening method is most cost effective. Cologuard's sensitivity and specificity in 
detecting CRC is 92% and 84%. High-sensitivity fecal occult blood test (FOBT) has a sensitivity 
ranging from 62-79% and a specificity ranging from 87% to 96% (US Preventive Services Task 
Force, 2016). Overall, the USPSTF acknowledges that there are multiple screening tools 
available, each with their own advantages. Their overall position statement is "the best screening 
tests is the one that gets done" (US Preventive Services Task Force, p. 2573, 2016).  
 There are many factors and barriers that impact people receiving CRC screening during 
the recommended age range. Many studies have found that a team-based approach involving 
clinic staff can help increase CRC screening rates (Basch, 2015; Baxter, 2017; Potter et al., 
2009).  Healthcare professionals are aware of the importance of CRC screenings and the impact 
it has on people's health. However, CRC screening rates remain low and thousands of people die 
each year from CRC. Previous successful approaches to this problem include using multiple 
strategies to increase screenings, involving nonclinical staff, and incorporating a shared decision 
model with patients so they can make the best-informed decision (Schroy et al., 2016; Potter et 
al., 2009).  
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 Colorectal cancer is the second leading cause of cancer-related deaths in the United 
States among men and women, even with the current screening options available. Worldwide, 
CRC is the third most common cancer, affecting approximately 1.4 million people in 2012 
(World Cancer Research Fund International, 2017). In 2016, approximately 134,000 people were 
diagnosed with CRC, accounting for approximately 49,000 deaths (USPSTF, 2016). The 
USPSTF finds that "screening for colorectal cancer is a substantially underused preventive health 
strategy in the United States" (USPSTF, 2016). In addition, one of the goals of Healthy People 
2020 is to reduce the number of cancer-related deaths through early detection and treatment 
(Healthypeople.gov, 2017). The USPSTF currently recommends screening for colorectal cancer 
for both men and women between the ages of 50 to 75 years. Preventative screenings are 
recommended for patients that are at average risk and who are asymptomatic, meaning no family 
or personal history of CRC, blood in their stool, iron deficiency anemia, or personal history of 
irritable bowel disease (IBD) or Crohn's disease (USPSTF, 2016). According to the Colon 
Cancer Alliance (2017), 50% of new CRC cases occur in people age 50 and older. People with 
first degree relatives who have had CRC have increased risk and should be screened earlier. It is 
recommended that African Americans have their first screening at the age of 45 years.  
 Current CRC screening rates remain low, even with advanced screening options 
available. It is estimated that only one in three adults receive some form of CRC screening 
between the ages of 50 to 75 years (American Gastroenterological Association, 2017). Colorectal 
cancer can be caught early with regular screenings. Early detection and treatment leads to better 
patient outcomes and decreased mortality. Multiple guidelines recommend the first screening for 
CRC between the ages of 50 to 75 years. Follow up screenings after initial screenings vary based 
off findings from the first colonoscopy and family history. 
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Problem Statement & Picot 
 In a primary care setting in the Southwest United States, CRC screening 
recommendations are being offered at annual visits by primary care providers, if a patient present 
with symptoms, or if the patient brings up the topic. There is no unified or team approach to 
CRC screenings. There is also a lack of follow up by primary care providers after the 
recommendations are given. Often the provider's only way of knowing if the CRC screening was 
completed is when a report is sent by the gastroenterologist after the visit. This places the 
responsibility of completing the screening on the patient alone. This assessment has led to the 
clinically relevant PICOT question, in patients between the age of 50 and 75 years old requiring 
screening for colorectal cancer (P), how does offering stool DNA testing and FIT testing in 
addition to a screening colonoscopy (I), compared to offering a screening colonoscopy alone (C), 
affect the number of patients completing their colorectal cancer screening (O), over a two-month 
period (T)? 
Search Strategy 
 To answer this clinically relevant question, an exhaustive search of the literature was 
performed. Databases searched included Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), PubMed, and The Cochrane Library.  
CINAHL 
 The key term colorectal cancer screening for a yield of 2,775 citations. Then methods of 
colorectal cancer screening was searched for a yield of 178 papers. Combining these terms with 
the Boolean connector AND resulted in 169 citations. Then the key search terms fecal 
immunochemical, FIT, colonoscopy, flexible sigmoidoscopy, guaiac fecal occult blood test, and 
stool DNA were searched independently and then combined with the OR connector for a total 
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yield of 8276 papers. The terms primary care were then searched independently and then 
combined for a total of 85,436 citations. When all major concepts were then combined, there was 
a total yield of 427 citations. Further limitations included studies completed in the United States 
or Canada only, adult populations age 50-75 years old and studies completed between 2009-2017 
for a yield of 66 studies. Rapid critical appraisals were performed using a standardized checklist 
form on these remaining studies with 7 being retained for further evaluation.   
PubMed 
 Initial search phrase using PubMed included colorectal cancer screening, stool DNA, and 
FIT for a yield of 32 results. Additional criteria of studies between the year 2009-2017 were 
added to yield 30 results. Limiting studies to clinical trials only yielded 2 results, therefore the 
limitation was removed for a total of 30 studies. The terms primary care and practitioner were 
searched independently within these studies. After a rapid critical appraisal two were retained for 
further evaluation.  
The Cochrane Library 
 Lastly, a search using The Cochrane Library was performed with key terms colorectal 
cancer screening which had an initial yield of 1,962 results. Additional key terms were added to 
include stool DNA, FIT, and primary care. The term primary care yielded too many results at 55, 
690 results. Ultimately this term was removed to yield a final of 7 studies.  
 After rapid critical appraisals, ten studies were retained for further evaluation (Appendix 
H). These studies were chosen based on their relevance to the PICOT question, their level of 
evidence, and quality of their study. Those that were excluded were of low quality, poor study 
design, or were not relevant.  
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Evidence Synthesis 
 The ten chosen studies were further critically evaluated and were entered into an 
evaluation table (Appendix A) to better allow for synthesis of evidence. The studies include six 
randomized control trials (RCT), one survey, two systematic review and meta analyses, and one 
cross sectional study. Varying levels of evidence were included among the studies, six of which 
were high level I, one level IV, two level V, and one level VI. Large samples sizes were included 
in all the studies. One study included a large degree of bias due to the funding of the study being 
the maker of the only stool DNA test available on the market currently. This study was still 
included due to the high sensitivity and specificity of the test in detecting CRC and its innovative 
testing capability. All studies included CRC as its main area of focus, with all but three having a 
positive impact on CRC screening status. All but two studies approached screening for CRC in 
different ways. There were a wide variety of measurement tools used, likely due to various 
healthcare settings, resources, and different healthcare systems. Measurements consisted of CRC 
screening status completion rates, intent to screen, or provider satisfaction with available 
screening tools. Validity and rate of detection for polyps were included in one study due to the 
nature of the study in evaluating FIT and stool DNA tests. Two studies evaluated physician's 
roles and involvement in CRC screening and took this into consideration with their results. Three 
studies included a multidisciplinary team approach and its effect on CRC screening status. Only 
one study cited a specific theoretical framework to guide its design.  
 A high degree of homogeneity was identified with regards to the study population and 
demographics. This is due to the population most commonly affected by CRC and recommended 
screening guidelines by the USPSTF. There was moderate heterogeneity regarding populations 
having health insurance, being an underserved population, and ethnicity.  There was a moderate 
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degree of heterogeneity in regard to interventions implemented, due to the wide variety of CRC 
screening tools available. While there was high homogeneity regarding outcomes measured, 
being CRC screening status, some studies also measured physician involvement, support staff 
involvement, patient reminders, and the use of decision aid tools. The most common CRC 
screening tools studied were colonoscopy, FIT, and gFOBT. This synthesis of evidence and 
current CRC screening guidelines supported the PICOT question a provided reasoning for 
implementing a project change that would increase CRC screening rates (Appendix B).  
Purpose Statement 
 The purpose of this project was to implement a change in workflow to increase colorectal 
cancer screening rates and improve Meaningful Use scores in a primary care setting.  
 Meaningful Use was introduced by the United States government in 2009 as part of the 
Health Information Technology for Economic and Clinical Health Act (HITECH). The goal of 
Meaningful Use was to encourage health care providers to adopt electronic health records system 
to improve the quality, safety, and efficiency of patient care. Meaningful Use sets specific 
objectives for health care providers and hospitals to achieve to qualify for Centers for Medicare 
and Medicaid Services Incentive Programs. Documenting colorectal cancer screening status and 
recommending CRC screenings to patients is one of the objectives of Meaningful Use and is 
considered a Clinical Quality Measure (HealthIT.gov). 
Evidenced Based Practice Model And Conceptual Framework 
 The Health Belief Model (HBM) (Appendix C) guided the proposed project design. The 
HBM was developed in the 1950's and explores why people do not partake in health-screening 
programs (Ueland, Hornung, and Greenwald, 2006). This model has been used in multiple 
studies to explore CRC screening uptake. The HBM has six key concepts; perceived 
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susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-
efficacy (Ueland, Hornung, & Greenwald, 2006). The HBM was chosen for this practice change 
because CRC is considered a preventable cancer if caught early on with CRC screenings. 
Patient's belief of a perceived threat, CRC, and perceived benefits of screening, can improve 
outcomes and promote self-efficacy when they decide to have CRC and within the recommended 
timeframe.  
 The Ottawa Model of Research Use (Appendix D) was used as the Evidence Based 
Practice (EBP) to facilitate practice change. The Ottawa Model consists of six steps that are used 
to guide research into practice (Logan, Harrison, Graham, Dunn, and Bissonnette, 1999). The 
Ottawa Model is widely used in research and is recognized for its ability to implement EBP. The 
structured approach of assessing barriers and facilitators, monitoring interventions, and 
evaluating outcomes was the reason this model was chosen. The Ottawa Model takes the patient, 
practitioner, and environment into consideration to implement a change in practice, all are 
important factors when it comes to CRC screening. This model provided a systematic and 
collaborative approach to adopting changes in the way the practice approaches CRC screening.  
Project Methods 
 Ten primary care physicians (PCPs) and their medical assistants (MAs) at the designated 
clinic were offered to participate in this evidence-based practice change project. The participants, 
primary care providers, DNP student, and medical assistants, were expected to spend 
approximately 8-10 weeks participating in the practice change, or until up to 300 patients had 
been offered screening.  Ultimately, five PCPs and five MAs chose to participate in this practice 
change. Project data collection took place between October 2017 and February 2018.  
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          Institutional review board (IRB) approval was received on September 7th, 2017 and 
granted by Arizona State University. The DNP student then met with PCPs, MAs, and the office 
manager to begin the project. Information on the project design, goals and purpose of the 
practice change were discussed with individuals during one-on-one meetings at the clinic site. 
An information sheet about the project was provided at these one-on-one meetings. The Practice 
Culture Assessment (PCA) survey (Appendix E) was used to measure perceptions of the practice 
culture. The PCA is a 22-question tool designed to measures perceptions related to practice 
function and successful implementation of practice quality improvement; permission to use this 
survey was granted from one of its authors Dr. Perry Dickinson. The PCA has been used in 
multiple studies to evaluate workplace change (Dickinson et al., 2015; Jaén et al., 2010). This 
survey acted as a pre and post survey that was given at the beginning of the project and when the 
project was finished. The attendance at the educational meeting and completion of the PCA 
survey was used as consent to participate in the practice change. Participants were given a unique 
subject ID code to match pre and post surveys; all participants responses remained anonymous.  
       Once participants were recruited to participate, the practice change began. Medical assistants 
identified patients that meet criteria for CRC screening based on the education they received 
during the education meeting and they were instructed to follow a CRC Screening Flowsheet 
(Appendix H) provided to them. If eligible patients did not have any form of CRC screening 
documented in their electronic health record (EHR), stated they had not had a screening, or were 
due for repeat screening, the medical assistant handed patients the CDC Designed Colon Cancer 
Educational Brochure (Appendix F). After patients left their appointment, the medical assistant 
filled out a brief DNP project form and circled "Yes" or "No" questions to identify the 
appropriate course of action and a multiple-choice question that delineated which tests patients 
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chose most frequently (Appendix G). This CRC Screening Evaluation Form was used for dual 
purpose, both for standard of care and for this project. No patient identification was present on 
these Evaluation Forms. 
 The DNP student was present for the first 2 to 3 weeks of the practice change to answer 
any questions or concerns the PCPs or medical assistants have. She was also available via email 
and telephone. This process continued from October 2017 to February 2018. After project 
completion, PCPs and medical assistants were given the PCA Survey again to evaluate for 
personal perceptions on practice change.  
     Meaningful Use scores were provided to the DNP student by the office manager and IT 
personnel to evaluate for any changes in scoring. 
 SPSS23 was used to store and analyze data. The DNP student analyzed data and ran 
reports with the help of an assigned statistician at Arizona State University (ASU) College of 
Nursing and Heath Innovation (CONHI). A paired t-test was used to measure pre and post survey 
data. Means of quantitative data were reported from the CRC screening evaluation forms. 
Meaningful Use scores pre and post project will be provided by the project site practice 
administrator. After data analysis, an executive summary was provided to the primary care 
practice to explain the results of the project and recommendations for further action. $396.36 was 
spent on this project from the DNP student's personal funding. No outside funding was received 
for this project.  
Project Results 
Meaningful Use 
 Meaningful Use scores were expected to improve from October to February, which is 
when data collection and project implementation took place. Meaningful Use Scores prior to 
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project implementation were provided to act as a baseline. 1/4/17 to 4/3/17 at 14.9%, 4/4/17 to 
7/2/17 at 15.17%, and 7/3/17 to 9/30/17 at 15.58%. The first Meaningful Use scores that were 
reported during the practice change were from 10/1/17 to 12/29/17 at 15.36%. Scores decreased 
slightly from October to December, possibly due to the holiday season and increased incidence 
of acute illness such as flu. Data from January and February 2018 were not able to be obtained 
due to the practice only receiving reports biannually. Unfortunately, this was not made clear to 
the DNP student early on so data from these two months will not be obtained. It was hoped that 
data would have been highest in January and February 2018. Since this information was not 
provided in time, the practice manager will evaluate 2018 data on her own and provide feedback 
to the practice on her own terms.  
CRC Screening Evaluation Forms 
 A total of 91 patients were screened during the project, N=91. Of those screened, 8% did 
not meet screening criteria. 67% reported they had already had screening, but documentation was 
not entered in the clinical decision support system (CDSS) section of the chart; documentation 
was added by the MAs. This shows that the MAs have the ability to improve Meaningful use 
scores for the practice simply by following this new workflow. If patients have been screened, 
but it is not documented in the correct spot in the EHR, data is being missed and Meaningful Use 
scores cannot improve. Adding documentation to CDSS ensures that Meaningful Use scores are 
captured when reports are run and ensures that CRC screening status is being charted 
consistently in the same spot by all providers. 70% of those screened were given a CRC 
Screening Brochure by the MAs. The most common method of screening chosen was 
colonoscopy, 87%. 3% chose FIT, 3% chose stool DNA, and 7% did not choose any form of 
screening. A strong correlation was found between receiving a CRC brochure and choosing a 
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form of screening. A Pearson correlation coefficient was calculated for the relationship between 
patient's receiving a brochure and choosing a form of screening. A strong correlation was found 
(r (-.293) = .01, p <.05) between receiving a CRC brochure and choosing a form of screening. 
This indicates patients are more likely to choose a screening method when they receive a CRC 
screening brochure. 
Pre and Post PCA Surveys 
 The sample consisted of N=9; 4 (44%) PCPs and 5 (56%) MA's. One survey had to be 
thrown out due to lack of a corresponding pre-survey. A paired-samples t test was calculated to 
compare the mean pre-survey scores to mean post-survey scores. No significant difference from 
pre to post survey satisfaction scores were found (t (8) = -1.542, p = .162). It was observed that 
participants were reluctant to complete these surveys due to time and the number of questions 
involved. Some participants took a few days to return surveys while one took two weeks to 
return a post-survey. Two participants questioned the surveys, asking how they were relevant to 
the project.  
Discussion 
 This change in workflow allowed for staff and patient education regarding CRC. 
Providers and MAs learned of new documentation techniques that would allow the eClinical 
Works EHR to capture more data regarding Meaningful Use. While Meaningful Use scores are 
not back yet for 2018, it is important for staff to document in the same spot, CDSS, for this data 
to be captured. The practice manager reported that Meaningful Use data is only retrievable twice 
a year, making it more difficult to monitor this information on a monthly basis. The project 
champion and physician provider expressed liking the CRC Screening Brochures because they 
were any easy way to approach the topic. The DNP student discussed with the practice manager 
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if or where they would like to continue having the brochures available for patients. Patients and 
providers overwhelmingly chose colonoscopy as the most common method of screening, which 
research shows as the most common method currently. With the advancement of stool DNA 
testing, these numbers may change in the future.  
 Originally the goal was to screen 300 patients at the clinic, however MAs began 
screening patients less as time went on. When asked how the change in work flow was going, 
simple answers were given such as "fine" or "most people are screened already". This may have 
indicated a lack of understanding on the importance of continued screening and the need to raise 
the topic of CRC screening. Data does not support that most people are screened in this office in 
spite of the MAs thinking this is the case. With fewer CRC Screening Forms being returned as 
time progressed, the decision was made to stop the project October with N=91 of patients 
screened. MAs indicated this project did create extra work for them during their already busy 
schedule and could be another factor for not reaching the original goal of 300 patients.  In 
reviewing the practice change, the MAs said filling out additional forms to capture data was time 
consuming for them, and some expressed they "asked but forgot to fill out forms". Time is a 
constant issue when making any workplace change. If this practice change were to continue, 
forms and additional paperwork would be removed from the daily tasks. Instead, Meaningful 
Use data would be the only method to capture uptake of screening patients and documenting in 
the correct area of CDSS within eClinicalWorks. Many corporate organizations and companies 
have mandatory compliance with Meaningful Use documentation and is stated so in their 
organization policy. The fact that this practice is a private organization with no hospital 
affiliation or larger organization overseeing their documentation process could be another reason 
for decreased uptake of documentation. If the practice were to make this practice change an 
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actual policy in their practice, uptake and compliance may increase, making this a sustainable 
practice change.  
 Participants had trouble remembering their unique subject ID assigned to them to match 
pre and post survey data. In the future a simpler ID code should be used to avoid confusion to 
participants. There was no significance found between pre and post survey data. This could be 
due to the length of time the providers and MAs have been at the clinic, and their perceived 
belief that their work flow did not need to change, which is stated in the Ottawa Model of 
Research Use (Appendix C). Follow up meetings and discussions regarding the importance of 
capturing Meaningful Use data, how it affects patients and the practice as a whole, could help to 
facilitate workplace change in the future. If this project were to be repeated a different pre and 
post survey tool that was shorter in length would have been chosen. A post-survey asking about 
perceptions of this project change with an open area for comments would have provided useful 
feedback to see what participants liked or did not like about this project.  
Conclusion 
 Further follow up is needed to evaluate cost effectiveness and sustainability of this 
practice change. Data for Meaningful Use is only available biannually and must be requested 
either by IT or the practice manager. The practice manger mentioned looking into this and 
working with the newly hired IT staff to see if data can be reported more frequently. This would 
allow for closer monitoring of this data and provide the practice with a more real-time accurate 
result of CRC screenings on a monthly basis. The eClinical Works EHR does not automatically 
report such data, so additional staff resources are required to continue measuring outcomes. It is 
recommended that IT continue to pull this data, so the practice can have an accurate idea of 
where they stand in capturing CRC screening Meaningful Use rates. Continued staff education is 
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recommended to ensure everyone is documenting CRC screening status is the same location in 
the EHR. Printing of CRC Screening Brochures would need to be calculated into annual budget 
if the practice wishes to continue making them available for patients. Overall, 91 patients had the 
topic of CRC screening brought to their attention, which is a great start in the early detection of 
colorectal cancer. Only five providers in this practice chose to participate in this study. If all 
providers in the practice implemented this change in work flow it is likely that more patients 
would get screened on a more consistent basis. This practice is a private practice and does not 
have to follow any specific policies such as larger organizations do. A set policy on CRC 
screening and documentation could help to increase CRC screening rates at this clinic if the 
practice chose to enact such a policy. Having a champion of change among the MAs in addition 
to the PCPs could also have a positive result on sustaining this change. Ultimately the data shows 
that receiving a CRC screening brochure likely increase the likelihood of a patient choosing a 
form of screening, which was the goal of this project.  
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ACN-advanced colorectal neoplasia, ACNI-Advanced colorectal neoplasia index, AD- academic detailing, BE- barium enema, CA- cancer, CAPE-Client 
Agency Program Enrollment, CI- confidence interval, CRC-Colorectal cancer, CS-colonoscopy, CT- computed tomography, DA-decision aid, DNA- 
deoxyribonucleic acid, DRE- digital rectal exam, EMR- electronic medical record, FAP- familial adenomatous polyposis, FIT- fecal immunochemical test, 
FOBT-fecal occult blood test, FS- flexible sigmoidoscopy, gFOBT, guaiac fecal occult blood testing, HA- hazard ratio, HNPCC- hereditary nonpolyposis 
colorectal cancer, IBD-inflammatory bowel disease, IBS- irritable bowel syndrome, ICES-Institute for Clinical Evaluation Sciences, iFOBT- immunochemical 
fecal occult blood test, IPDB-ICES Physicians’ Database, N-number of participants, n-subset of participants, NNS- number needed to screen, OR-odds ratio, 
OHIP- Ontario Health Insurance Plan, PCP- primary care physician, PEM1- printed educational materials, PEM2- Patient Enrollment Model, PT-patient, 
QBE- question-behavior effect, QI-quality improvement, RCT-randomized control trial, RPDB- Registered Persons Database, SCOPE-The Supporting 
Colorectal Cancer Outcomes through Participatory Enhancements, SDM-shared decision making, SDMP-satisfaction with decision making process, SS-
statistically significant, TTE-tailored telephone education, UC- ulcerative colitis, UTD-up to date 
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Evaluation Table: Colorectal Cancer Screening 
Citation Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Basch et al., (2015). 
A Randomized trial 
to compare 
alternative 
educational 
interventions to 
increase colorectal 
cancer screening in a 
hard-to-reach urban 
minority population 
with health insurance. 
Funding: American 
Cancer Society 
Grant: Identifier 
NCT02392143 
Bias/Conflict: $20 
promised to PTs to 
complete study 
USA- NYC 
 
Health 
Promotio
n Model- 
Nola J. 
Pender 
Design: RCT 
 
Purpose: To 
compare 
interventions to 
increase CRC 
screenings in 
those with health 
insurance  
N= 8792 
n=564 PTs randomized 
Inclusion criteria: Adults age 
50-75 years with health 
insurance (union-based self-
administered and self-insured 
benefit fund). Currently out of 
compliance with recommended 
CRC screening. Having a 
"regular doctor", a stated 
intention to remain in the 
benefit fund for at least 1 year. 
Reachable by telephone, able to 
communicate in English, ability 
to give consent. 
Exclusion criteria: No health 
insurance. Hx of colorectal 
polyps, IBD, IBS, Crohn's 
disease, UC, or current 
treatment for any type of CA.  
IV 1: PEM1 
Only 
IV 2:AD Only 
IV 3:AD & 
TTE 
 
DV: CRC 
screening status 
 
*PEM1-
highlighted 
colonoscopy as 
being the only 
test that can 
identify & 
prevent CRC, 
but explained 
other CRC 
screening tests 
3 types data 
collection: 
Baseline survey 
data. 
Implementation 
data.  
Outcome data 
based on 
medical claims.  
Pairwise group 
differences 
using 2x2 χ2 
analyses. 
Linear trends 
across groups.  
N% 
screened for 
CRC: 
PEM only 
N=18.3%. 
AD only 
N=20% 
AD&TTE 
N=25.6%. 
Total N= 
21.5% 
No 
statistically 
significant 
pairwise 
differences 
between 
groups in 
screening 
rate 
 
Level I 
Strengths: RCT. 
TTE based on 
previously tested 
model. 
Weaknesses: No 
theoretical 
framework named. 
Poor follow up with 
participants after 1 
year. NYC already 
has high rate of 
CRC screening in 
the country.  
Conclusion: 
Screening rate was 
almost 40% higher 
in AD&TTE group 
vs PEM- but was 
not SS 
Citation Theory/ Design/ Sample/ Setting Major Measurement Data Findings/ Level of 
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Concep
tual 
Frame
work 
Method Variables & 
Definitions 
/ 
Instrumentati
on 
Analysis 
 
Results Evidence; 
Decision for 
practice/ 
application to 
practice 
Baxter et al., (2017). 
Do primary care 
provider strategies 
improve patient 
participation in 
colorectal cancer 
screening? 
 
Funding: Canadian 
Cancer Society (grant 
#2011-700803).  
Cancer Care Ontario 
& Canadian Institutes 
of Health Research 
Foundation Grant 
(Competition 
#201509).  
 
Bias/Conflict: None 
Setting: Ontario, 
Canada 
 
 
 
 
Adaptati
on 
Model- 
Roy 
Design: Cross-
sectional survey 
 
 
Purpose: To 
determine the 
effect of provider 
strategies to 
increase screening 
in a single-payer 
system.  
n=717 PCPs 
n= 147,834 rostered PTs 
Inclusion Criteria: 
PCPs: practicing PCPs with a 
valid unique physician 
identifier in IPDB. Belong to a 
PEM2 identified in CAPE.  
PTs: Receiving comprehensive 
primary care including CRC 
from a specific PCP. Eligible 
for CRC screenings (age 50-74) 
at any point from 4/1/2012 to 
3/31/2013 according to RPDB.  
Exclusion Criteria: 
PCPs: retired, not complete 
initial survey, not in Ontario 
province, main practice not 
primary care.  
PTs: Residence not Ontario as 
of 3/31/2013, no contact with 
healthcare system within > 6 
years prior to 3/21/13, if first 
OHIP eligibility was later than 
3/31/2013, if dx of invasive 
CRC prior to 4/1/2012. 
Underwent colonic resection 
prior to 4/1/2012l, if PT died 
before 3/31/2013.  
IV1: Survey to 
PCP to identify 
covariates 
 
  
DV: Time to 
become up to 
date with CRC 
screening status 
 
 
Mailed surveys.  
 
Modified 
Dillman-style 
multimodal 
approach.  
 
Cox 
proportional 
hazard models.  
SAS statistical 
software.  
 
Descriptive 
Statistics.  
Regression 
analyses 
Multiple 
PCP 
strategies 
(HR=1.27, 
95% 
CI:1.16-
1.39, 
P<0.0001 
for PCPs 
using 4-5 vs 
0-1 
strategies). 
Systematic 
approach for 
screening 
weakly 
associated 
with 
screening 
uptake 
(HR=1.14, 
95%CI: 
1.03-1.26, 
P=0.04>5 
years 
overdue vs 
<1 year 
overdue 
Level VI 
Strengths: Large 
study. Strong 
heterogeneity of PT 
population.  
Weaknesses: No 
theoretical 
framework used. 
Population based 
survey. Different 
types of CRC 
screenings not 
explained.   
Conclusion: No 
single strategy was 
strongly associated 
with screening.  
PCP use of multiple 
strategies > 
screening uptake.  
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Citation Theory/ 
Concep
tual 
Frame
work 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Fitzpatrcik-Lewis et 
al., (2016). Screening 
for colorectal cancer: 
a systematic review 
and meta-analysis 
 
Funding: Public 
Health Agency of 
Canada and the 
Canadian Institutes of 
Health Research.  
 
Bias/Conflict: None. 
 
Setting: Ontario, 
Canada 
 
 
System's 
Model- 
Neuman 
Design:  
Systematic review 
and meta-analysis 
 
 
Purpose: To 
evaluate the 
effectiveness of 
CRC screening in 
asymptomatic 
adults.  
87 Included Studies 
 
Inclusion criteria: Average 
risk, asymptomatic adults age > 
18 years. CRC screening with a 
CS, CT, colonography, gFOBT, 
iFOBT, FS, BE, DRE, fecal 
DNA & other identified tests. 
Primary care setting a PCP 
could refer to for colonoscopy, 
CT and FS testing. RCT with 
comparison groups of no 
screening or comparison 
between tests. Harms: any 
study.  
Exclusion criteria: High risk 
adults with FAP, HNPCC, 
history of IBD, personal history 
of polyps or CRC; adults with 
symptoms suggesting 
underlying CRC or with known 
genetic mutations associated 
with increased CRC risk. Case-
finding or surveillance tests.  
 
IV1: 
effectiveness of 
each CRC 
screening test to 
reduce CRC-
specific 
mortality, all-
cause mortality, 
or incidence of 
late-stage CRC 
IV2: Optimal 
age to start & 
stop screening 
IV3: Optimal 
screening 
interval 
IV4: Benefits 
of different 
screening tests 
IV5: Incidence 
of harm 
DV: CRC 
screening 
recommendatio
ns 
Data extraction 
completed by 
one reviewer 
and verified by 
a second using 
standardized 
forms- all 
checked by 
statistician 
before analysis.  
 
RCTs appraised 
using Cochrane 
Risk of Bias 
tool & Grade 
Recommendatio
ns Assessment, 
Development 
and Evaluation 
(GRADE) 
system.   
Risk ratios 
using 
DerSimonian 
and Laird 
random-effects 
model with 
inverse 
variance 
method.  
 
Binomial CIs 
calculated by 
Wilson score 
interval 
method. 
Review 
Manager 5.3, 
STATA 12, 
and 
GRADEpro 
IV1: gFOBT 
& FS 18% 
reduction 
IV2: older 
adults ≥ 60 
IV3: No 
change 
between 
biennial and 
annual 
gFOBT 
screening 
IV4: gFOBT 
& FS most 
benefit 
IV5: FS 
potential 
harm 
DV: iFOBT 
higher 
sensitivity 
and 
specificity 
 
 
 
 
 
 
 
 
Level V 
Strengths: Large 
review.  
Weaknesses: No 
consideration of PT 
preference. No 
consideration of 
implementation.  
Conclusion: CRC 
screening using 
FOBT and FS is 
effective for 
reducing CRC 
mortality and 
incidence of late-
stage disease  
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Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Gupta et al., (2013). 
Comparative 
effectiveness of fecal 
immunochemical test 
outreach, 
colonoscopy 
outreach, and usual 
care for boosting 
colorectal cancer 
screening among the 
underserved 
Funding: Cancer 
Prevention and 
Research Institute of 
Texas, National 
Institutes of Health- 
Grants 
 
Bias/Conflict: None 
Health 
promotio
n model- 
Pender. 
 
Design: RCT 
 
Purpose: Increase 
CRC screening- 
through mailed 
outreach & FIT 
offering vs 
colonoscopy  
 
 
 
 
 
 
 
 
 
 
 
N=5994 
 
Inclusion Criteria: uninsured 
PTs not UTD with CRC 
screening, age 54-64 years, 
served by the John Pete Smith 
Health Network, a safety net 
health system. 
 
Exclusion Criteria: UTD CRC 
screening status, no address or 
phone number on file, language 
other than English or Spanish, 
history of CRC, IBD, polyps, 
no recent health system visit, 
incarceration.  
IV1: FIT 
outreach 
IV2: CS 
outreach 
IV3: Usual care 
DV: CRC 
screening test 
within 1 year 
SAS PROC 
PLAN 
 
CPT codes 
 
FIT test 
interpretation 
by healthy 
system clinic 
laboratory 
 
 
 
 
 
 
 
 
 
SAS Software 
 
2-sample t test 
χ2 or Fisher 
exact test 
 
2 primary 
comparisons, 
P<.025 SS 
 
All other 
comparisons, 
P<.05 SS 
FIT tripled 
CRC 
screening 
rates, CS 
doubled 
rates 
compared 
with usual 
care (40.7%, 
24.1%, and 
12.1%).  
  
P<.001 
Level I 
Strengths: Size of 
study. Level of 
evidence.  
Weakness: No 
theoretical 
framework noted. 
Less PTs were 
randomized to CS 
outreach overall vs 
other groups. 
Uninsured PTs 
unlikely to get 
colonoscopy 
regardless due to 
lack of payment 
method.  
Conclusion: FIT > 
vs CS. No 
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Setting: USA- Texas 
 
 
 
 
 
 
 
 
 
 
intervention results 
in overall less CRC 
screening 
Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Hoffman et al., 
(2010). Comparative 
Effectiveness of 
Multifaceted 
Outreach to Initiate 
Colorectal Cancer 
Screening in 
Community Health 
Centers. 
Bias/Conflict: None 
Funding: 
Department of 
Veterans Affairs 
(project number 
SHP 08-177)  
USA 
Health 
promotio
n model- 
Pender. 
 
Design: RCT 
Purpose: 
Determine 
whether CRC 
screening 
adherence is 
greater with FIT 
or gFOBT  
 
FIT n= 202 
gFOBT n= 202 
 
Setting: New Mexico Veterans 
Affairs Health Care System 
Primary Care Clinic 
 
Inclusion: ICD-9 problem lists, 
CPT procedure codes, 
pathology records, and 
screening reminders to identify 
primary care PTs age 50-80 
years due for CRC screening.  
Exclusion: PTs with CRC, 
IBD, polyps.  
IV1: FIT 
IV2: gFOBT 
DV: CRC 
screening 
adherence  
Random digit 
number 
generator 
(http://www.ran
domizer.org/)  
used to assign 
subjects to 
receive either 
FIT or gFOBT. 
FIT tests 
analyzed on the 
OC-Auto Micro 
80 instrument; 
human 
hemoglobin 
levels N 100 
ng/ml were 
considered +.  
-Descriptive 
statistics with 
95% CI.  
-t-tests or 
Wilcoxon two-
sample test for 
continuous 
variables, & 
chi- square 
tests for 
categorical 
variables.  
-Multivariate 
logistic 
regression 
modeling to 
compare 
adherence  
Screening 
adherence 
was higher 
with FIT 
than gFOBT 
(61.4% vs. 
50.5%, P = 
0.03). The 
adjusted 
odds ratio 
for 
completing 
FIT vs. 
gFOBT was 
1.56, 95% 
CI 1.04, 
2.32.  
 
Level I 
Strengths: Level of 
evidence, size of 
study.  
Weaknesses: VA 
population only. 
Motivated PTs only 
consented to study.  
Conclusion: FIT > 
gFOBT CRC 
screening status.  
Citation Theory/ 
Concep
tual 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
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Frame
work 
 
on practice/ 
application to 
practice 
Imperiale et al., 
(2014). Multitarget 
stool DNA testing for 
colorectal-cancer 
screening 
 
Funding: Exact 
Sciences; 
ClinicalTrials.gov 
number, 
NCT01397747 
 
Bias/Conflict: 
Funded by Exact 
Sciences- maker of 
the stool DNA test 
(Cologuard- though 
not named in study 
directly) 
 
 
Health 
promotio
n model- 
Pender. 
 
Design: Cross-
sectional 
 
Purpose: To 
evaluate the 
multitarget stool 
DNA test as a tool 
for screening for 
CRC 
N= 9989 
Setting: 90 sites in US & 
Canada 
Inclusion Criteria: 
Asymptomatic PTs ages 50-84 
years considered average risk 
for CRC & who were scheduled 
to undergo screening CS.  
Exclusion Criteria: History of 
colorectal neoplasia, digestive 
CA, IBD; had undergone CS 
within previous 9 years or 
barium enema, FS within 5 
years; positive results of fecal 
blood testing within 6 months; 
undergone colorectal resection 
for any reason other than 
sigmoid diverticula; rectal 
bleeding within 30 days; 
personal or family history of 
CRC; had participated in any 
interventional clinical study 
within 30 days; or unable or 
unwilling to provide written 
informed consent.  
 
IV1: 
Multitarget 
DNA test 
IV2: FIT 
DV1: 
Sensitivity for 
detecting CRC 
DV2: 
Sensitivity for 
detecting 
advanced 
precancerous 
lesions 
DV3: Rate of 
detection of 
polyps 
One-sded 
McNemar 
paried-
comparions 
tests.  
 
Hanley-
McNeils 
method to 
calcuate P 
values 
SAS & 
StatXact 
software.  
IV1: 
Identified 60 
of 65 PTs 
with CRC; 
95% CI 
IV2: FIT 
identified 48 
of 65 CRC; 
95%CI 
DV1: 92.3% 
DNA, 
73.8% 
FIT(P=0.002
).  
DV2: 42/4% 
DNA; 
23.8% FIT 
(P=<0.001) 
DV3:  
69.2% 
DNA; 
46.2% FIT 
(P=0.004) 
NNS: 154 
with CS; 
166 DNA; 
208 FIT. 
 
Level IV 
Strengths: Use of 
additional CRC 
screening tool now 
available & shows 
promise. 
Weaknesses: Has 
bias. Does not 
discuss 
implementation to 
increase CRC 
screening rates. 
Does not discuss PT 
preferences. What is 
the cost? 
Conclusion: Stool 
DNA test has higher 
sensitivity but lower 
specificity for CRC 
detection.  
Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
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Potter et al., (2009). 
Offering annual fecal 
occult blood tests at 
annual flu shot clinics 
increases CRC 
screening rates  
Funding: Grants 
from the American 
Cancer society, 
Cancer Control 
Career Development 
Award for Primary 
Care Physicians, and 
the National Cancer 
Institute, Asian 
American Network 
for Cancer 
Awareness, Research 
& Training.  
Bias/Conflict: None. 
 
USA  
General 
Model of 
the 
Determin
ants of 
Behavior
al 
Change 
(a 
synthesis 
of 
behavior
al 
theories) 
Design: Time 
RCT 
 
Purpose: To 
determine whether 
providing home 
FOBT kits to 
eligible PTs 
during influenza 
inoculation clinics 
can contribute to 
higher CRC 
screening rates.  
N= 514 
Control n= 246 
Intervention n= 268 
 
Setting: Flu shot clinic 
 
Inclusion Criteria: PTs age 
50-79 years who were mailed 
flu shot campaign 
announcements & who attended 
the 17 flu shot clinic sessions. 
Had not had a FOBT since the 
end of prior flu season, a 
colonoscopy in past 10 years, 
any previously unevaluated 
abnormal FOBT results, or 
history of recent unevaluated 
rectal bleeding.  
Exclusion Criteria: Did not 
attend one of the 17 flu shot 
clinic sessions.  
 
 
 
IV1: PTs 
offered flu shots 
IV2: PTs 
offered flu shots 
and FOBT kits 
DV: CRC 
screening status 
 
Flu shot 
campaign 
announcements.  
 
Staff training 
sessions.  
 
Colorful 
multilingual 
education 
sheets.  
 
FOBT kits with 
postage-paid 
return 
envelopes.  
Stata software.  
Pearson χ2 for 
categorical 
variables.  
2-sample 
Wilcoxon test 
and McNemar 
test.  
Total PTs 
initially not 
UTD; 
Control n= 
20.7 % PTs 
who become 
UTD  
Intervention 
n= 68% PTs 
who became 
UTD P 
<.001 
Total PTs 
initially 
UTD; 
Control 
n=90.0%, 
Intervention 
n=98%, 
P<.005 
 
Level I 
Strengths: Strong 
theoretical 
framework. Well 
explained and 
deigned study.  
Weaknesses: 
Limited population- 
only those who 
attend flu clinics-
missing large 
portion of 
population. 
Conclusion: FOBT 
kits during flu 
season increased 
CRC rate. Needs to 
reach a broader 
population however. 
Multidisciplinary 
team approach 
works. 
  
Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Schroy et al., (2016). 
Risk stratification 
and shared decision 
making for CRC 
screening: a 
randomized 
controlled trial 
 
Health 
promotio
n model- 
Pender. 
 
Design:  
RCT, unblinded, 
parallel-group 
 
Purpose: To 
determine whether 
risk stratification 
for ACN 
n=352 
Setting: Boston Medical 
Center-private, not-for-profit 
community-based academic 
medical center. Largest safety 
net hospital in New England.  
Inclusion criteria: 
Asymptomatic average-risk 
IV1: Decision 
aide alone 
IV2: Decision 
aide plus risk 
assessment tool 
DV1: 
Concordance 
between PT 
Electronic risk 
assessment 
tool- pre and 
post-test for 
PTs. 
Web-based 
DVD-formatted 
decision aid for 
SAS software. 
 
P < 0.05 level  
 
 
  
IV1: 
Concordanc
e 88% 
IV2: 
Concordanc
e 85.6% 
DV1: DA 
only 88.0; 
Level I 
 
Strengths: Strong 
level of evidence. 
Validated tools 
used.  
Weaknesses: 
Unblinded. Single 
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Funding: National 
Cancer Institute 
Grant (RO1 
CA131197).  
 
Bias/Conflict: None 
 
USA 
influences 
provider 
willingness to 
comply with PT 
preferences when 
selecting a desired 
CRC screening 
option 
 
 
 
 
 
primary care PTs cared for at 
Boston Medical Center. Age 
50-75 years, under care of PCP, 
and due for CRC screening. 
Exclusion criteria: Lower GI 
symptoms or iron deficiency 
anemia, increased risk of CRC 
for which CS was the preferred 
screening method, lack of 
fluency in written & spoken 
English, comorbidities that 
precluded CRC by any method 
 
 
 
preference & 
test ordered 
DV2: PT 
satisfaction 
with decision-
making process.  
DV3: Screening 
intentions 
DV4: Test 
completion 
rates 
DV5: Provider 
satisfaction 
Definition: 
Concordance is 
defined as the 
number of 
patients who 
had their 
preferred test 
ordered (n) 
divided by the 
total number of 
patients who 
preferred the 
test (N).  
 
 
physicians- 
What Colon 
Cancer 
Screening Test 
is Best for You -
an educational 
website of the 
Section of 
Gastroenterolog
y at Boston 
University 
School of 
Medicine and 
Boston Medical 
Center that was 
created with 
funding for the 
Agency for 
Healthcare 
Quality and 
Research. 
 
ACNI P=0.72-
0.93 
 
Absolute risks 
assessment 
scores  
 
Brief paper-
based 3-item 
survey for 
providers 
12-item SDMP 
scale 
DA + ACNI 
85.6 P=0.40. 
DA + ACNI 
High risk 
83.5, DA + 
ACNI Low 
Risk 87.1 
P=0.51 
DV2: 
Concordanc
e n= 52.0, 
Discordance 
n=48.9, 
P<0.001 
DV3: 
Concordanc
e n= 4.6, 
discordance 
n=4.0, 
P<0.001 
DV4: 
Concordanc
e n= 109, 
discordance 
n=7, 
P=0.004 
DV5: SDM 
useful 
P=0.70, 
SDM will 
reduce time 
to decide on 
CRC 
screening 
P=0.10, 
reduces 
malpractice 
risk posttest 
institution setting. 
Lack of provider 
education for the 
study. Decision aid 
tool took between 
11-34 minutes- too 
much time in busy 
primary care setting 
Conclusion: PT 
preference an 
important factor to 
increase CRC rates. 
Web-DVD gave PT 
ALL the options for 
CRC screening- 
great web-based tool 
for education-this 
gave PTs multiple 
options for CRC 
screening 
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(validated) 
 
n=3.2.  
SDM 
positively 
effects CRC 
screening 
rates.  
Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Singal et al., (2016). 
Outreach invitations 
for FIT and 
Colonoscopy 
improve colorectal 
cancer screening 
rates.  
Funding: National 
Cancer Institute 
National Institutes of 
Health grant. 
Polymedco Corp. 
provided FIT test kits 
Bias/Conflict: 1 
author a paid member 
of Scientific 
Advisory Board for 
Exact Sciences for 
work performed 
outside current study 
USA 
Health 
promotio
n model- 
Pender. 
 
Design: 
Prospective RCT 
 
Purpose: 
Compare initial 
screening 
participation 
across the 3 
groups among 
individuals with at 
least 1 year of 
postintervention 
follow-up 
N=5999 
Setting: Primary care & 
hospital 
Inclusion Criteria: PTs age 
50-64 years, with at least 1 visit 
to PCP clinic within the year 
before randomization, residents 
of Dallas County, Parkland 
Health Plus coverage.  
Exclusion Criteria: UPD with 
CRC screening, no address or 
telephone number on file, 
language other than English or 
Spanish, history of CRC, IBD, 
polyps, or prior colectomy, 
incarceration.  
 
 
 
 
 
 
IV1: Usual care 
IV2: FIT 
outreach 
IV3: CS 
outreach 
 
DV: CRC 
screening status 
within 12 
months 
Querying 
electronic 
healthy system 
laboratory data 
for FIT testing 
& combination 
of test orders & 
administrative 
claims data for 
FS or CS 
Pearson chi-
square test 
 
SAS statistical 
software 
 
alpha .05 
IV1: 
Screening 
rates 29.6% 
IV2: 
Screening 
rate 58.8%. 
OR 3.39, 
95% CI 
IV3: 
Screening 
rate 42.4%. 
OR 1.00, 
95%CI 
Level I 
Strengths: 3-year 
study. Well 
designed study.  
 
Weaknesses: Lack 
of insurance could 
have skewed CS 
option 
 
Conclusion: FIT 
option increases 
CRC screening 
most, followed by 
CS.  
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Citation Theory/ 
Concep
tual 
Frame
work 
 
Design/ 
Method/Sampli
ng 
Sample/ Setting Major 
Variables & 
Definitions 
Measurement
/ 
Instrumentati
on 
Data 
Analysis 
 
Findings/ 
Results 
Level of 
Evidence; 
Decision for 
practice/ 
application to 
practice 
Volk et al., (2016). 
Patient decision aids 
for colorectal cancer 
screening: A 
systematic review 
and meta-analysis 
 
Funding: Award 
#R21CA132669 to 
Dr. Robert J. Volk 
form National Cancer 
Institute.  
 
 
 
Bias/Conflict: None.  
 
USA 
 
Systems 
Model of 
Clinical 
Preventiv
e Care 
Design: 
Systematic review 
and meta-analysis 
 
Purpose: To 
evaluate the effect 
of patient decision 
aids on CRC 
screening rates 
23 Articles; 21 trials including 
11,900 subjects.  
 
 
Inclusion Criteria: 
Quantitatively evaluated 
decision aid comparted to one 
or more conditions within a 
pre-post evaluation.  
 
Exclusion Criteria: Not 
relevant, an intervention that 
did not include trade-off 
information, decision aides did 
not have at least a pre-post 
design, decision aids did not 
report primary outcome 
findings.  
 
 
 
 
 
 
 
 
 
 
 
Studies 
evaluating 
patient decision 
aids for CRC 
screening in 
average-risk 
adults and their 
impact on 
knowledge, 
screening 
intentions, and 
uptake.  
IV1: Received 
decision aid 
IV2: Received 
general CRC 
screening 
information 
DV: CRC 
screening rates 
Variable per 
study; 
individual 
measurement 
tools not listed.  
Meta-analysis 
using a 
standardized 
form.  
PT exposed 
to DA = 
greater 
knowledge 
(mean 
difference = 
18.3 of 100; 
95%CI=15.5
, 21.1), more 
likely to be 
interested in 
screening 
(pooled 
relative risk 
= 1.5; 
95%CI =1.2, 
2.0), & more 
likely to be 
screening 
(pooled 
relative 
risk=1.3; 
95% 
CI=1.1,1.4) 
 
Level V 
Strengths: Large 
amount of studies 
included. 7 CRC 
screening options 
included in studies.  
Weaknesses: 
Multiple types of 
studies included. 
Multiple outcome 
scales used in 
studies.  
Conclusion: 
Decision aids 
associated with 
greater intentions to 
be screened & 
screening uptake 
 
 
 
